In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read More
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...
Read More
In a nutshell This study examined whether chromosomal abnormalities at diagnosis can predict treatment outcomes with TKIs in chronic myeloid leukemia (CML). Researchers reported similar long-term treatment outcomes in patients with and without chromosomal abnormalities at diagnosis. Some background CML is a disease in which the bone marrow makes...
Read More
In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...
Read More
In a nutshell This study compared the effectiveness of two types of tyrosine kinase inhibitors – imatinib (Gleevac) and bosutinib (Bosulif) – for chronic myeloid leukemia (CML). Researchers reported higher treatment response rates with bosutinib than with imatinib. Some background Many patients with CML...
Read More
In a nutshell This study examined the value of carrying out a bone marrow biopsy before beginning treatment for chronic lymphocytic leukemia (CLL). Researchers reported that a bone marrow biopsy at the time of diagnosis can help determine the need for treatment in CLL patients. Some background CLL is cancer of the blood and bone marrow. It is one...
Read More
In a nutshell This study reviewed evidence of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML). Some background CML is a disease in which the bone marrow makes too many mature and immature white blood cells. Most patients are diagnosed in the chronic (early) phase. Over recent years, targeted therapy with tyrosine...
Read More
In a nutshell This study examined treatment outcomes with dasatinib (Sprycel) for chronic myeloid leukemia (CML). Researchers reported a fast and strong treatment response to first-line dasatinib, particularly in older patients. The levels of a genetic mutation known as BCR-ABL1 at 3 months was found to be a predictor of treatment response. Some...
Read More
In a nutshell This study reviewed the occurrence and management of tumor lysis syndrome in patients receiving treatment for chronic lymphocytic leukemia (CLL). Some background Tumor lysis syndrome (TLS) is an uncommon but potentially life-threatening complication associated with the treatment of some cancers. TLS occurs when a large number of...
Read MoreIn a nutshell This paper studied hypogammaglobulinemia, an immune disorder, in patients with early-stage chronic lymphocytic leukemia (CLL). Researchers reported that low antibody levels at diagnosis did not increase the risk of a serious infection. However, patients with more aggressive disease are more likely to develop a late hypogammaglobulinemia....
Read More
In a nutshell This study examined outcomes after discontinuation of imatinib (Gleevac) in patients with chronic myeloid leukemia (CML). Researchers reported that some CML patients can safely discontinue imatinib after achieving a deep treatment response. Factors such as detectable residual leukemia cells after treatment affect the risk of losing...
Read More
In a nutshell This trial explored the effect of bosutinib (Bosulif) on the long-term health-related quality of life of chronic myeloid leukemia patients who did not respond to other treatments. This study concluded that bosutinib did not significantly affect long-term health-related quality of life. Some background Tyrosine kinase inhibitors...
Read More
